{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:32Z","timestamp":1792004372773,"version":"4.4.0"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI141349"],"award-info":[{"award-number":["AI141349"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,8,17]]},"abstract":"<jats:p>\n            Multidrug-resistant\/extensively drug-resistant (MDR\/XDR)\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            (PA) are critical antimicrobial resistance threats. Despite their increasing prevalence, treatment options for metallo-\u03b2-lactamase (MBL)-producing PA are limited, especially for New Delhi metallo-\u03b2-lactamase (NDM) producers. Pending further clinical studies, this case provides support for limited-scope use of cefepime-zidebactam for treating disseminated infections secondary to NDM-producing XDR PA.\n          <\/jats:p>","DOI":"10.1128\/aac.00663-23","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T14:00:22Z","timestamp":1688392822000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Case Commentary: Successful Use of Cefepime\/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-\u03b2-Lactamase-Producing\n            <i>Pseudomonas aeruginosa<\/i>\n            Infection in an Adult Patient with Acute T-Cell Leukemia"],"prefix":"10.1128","volume":"67","author":[{"given":"Stephanie L.","family":"Egge","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Houston Methodist Hospital, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"James S.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon, USA"},{"name":"Department of Pharmacy, Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Hakki","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Antibiotic resistance threats in the United States, 2019.","author":"CDC","year":"2019","unstructured":"CDC. 2019. Antibiotic resistance threats in the United States, 2019. U.S. Department of Health and Human Services, CDC, Atlanta, GA."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193431"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70168-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz416"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.07.012"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/652237"},{"key":"e_1_3_3_10_2","unstructured":"The Pew Charitable Trusts. 2014. Antibiotics currently in global clinical development. Updated 9 March 2021. https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/data-visualizations\/2014\/antibiotics-currently-in-clinical-development. Accessed 1 June 2023."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051068"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01432-20"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01582-20"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.10.007"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02011-21"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01697-22"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1909"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab311"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac241"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01600-22"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"e_1_3_3_22_2","unstructured":"Wockhardt Medpace Inc. 2021. Study of cefepime-zidebactam (FEP-ZID) in complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). ClinicalTrials.gov ID: NCT04979806. ClinicalTrials.gov U.S. National Library of Medicine Bethesda MD."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac233"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad061"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01854-22"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw593"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8010032"},{"key":"e_1_3_3_28_2","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"CLSI","year":"2023","unstructured":"CLSI. 2023. Performance Standards for Antimicrobial Susceptibility Testing, 33rd ed. CLSI supplement M100. CLSI, Wayne, PA.","edition":"33"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00397-20"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy955"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00663-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00663-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T13:01:37Z","timestamp":1692277297000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00663-23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,17]]}},"alternative-id":["10.1128\/aac.00663-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.00663-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"2023-07-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00663-23"}}